Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $36
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $30 to $36.
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $30 to $36.